加拿大礼来公司宣布,其用于治疗特应性皮炎(湿疹)的药物Ebglyss®已获得加拿大药物管理局-加拿大药物专家委员会(CDA-AMC)的长期期待的建议,并同时收到了泛加拿大制药联盟(PCPA)的意向书。
加拿大礼来公司宣布,其用于治疗特应性皮炎(湿疹)的药物Ebglyss®已获得加拿大药物管理局-加拿大药物专家委员会(CDA-AMC)的长期期待的建议,并同时收到了泛加拿大制药联盟(PCPA)的意向书。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.